Prevention of relapse of graves' disease by treatment with an intrathyroid injection of dexamethasone

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4984-4991

  Mao, Xiao Ming ^a   Li, Hui Qin ^a   Li, Qian ^a   Li, Dong Mei ^a   Xie, Xiao Jing ^a   Yin, Guo Ping ^a   Zhang, Peng ^a   Xu, Xiang Hong ^a   Wu, Jin Dan ^a   Chen, Song Wang ^a   Wang, Shu Kui ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHING SYNDROME; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; EUTHYROIDISM; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; HEADACHE; HEMATOMA; HUMAN; HYPERTHYROIDISM; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SIDE EFFECT; TASTE DISORDER; THYROTROPIN BLOOD LEVEL; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 73249129469     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1252     Document Type: Article

References (32)

1. Okamoto T, Iihara M, Obara T 2000 Management of hyperthyroidism due to Graves' and nodular disease. World J Surg 24:957-961
2. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS 2005 A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 153:489-498
3. Weetman AP 2000 Graves' disease. N Engl J Med 343:1236-1248
4. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S 2002 Graves' disease: drug regimens and predictors of outcome. Eur J Endocrinol 147:583-589
5. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 161:195-206
6. Inukai Y, Momobayashi A, Sugawara N, Aso Y 2007 Changes in expression of T-helper (Th)1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 156:623-630
7. Aniszewski JP, Valyasevi RW, Bahn RS 2000 Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 85:776-780
8. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E 2006 Interferon-γ inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J Clin Endocrinol Metab 91:614-620
9. Ajjan RA, Weetman AP 2004 New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 27:237-245
10. Xia N, Zhou S, Liang Y, Xiao C, Shen H, Pan H, Deng H, Wang N, Li QQ 2006 CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy. Int J Mol Med 17:911-916
11. Wiersinga WM, Smit T, Schuster-Uittenhoeve AL, van der Gaag R, Koornneef L 1988 Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves' ophthalmopathy. Ophthalmologica 197:75-84
12. Lacka K, Manuszewska E, Korczowska I, Lacki JK 2007 The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy. Curr Eye Res 32:291-297
13. Aktaran S, Akarsu E, Erbaoci I, Araz M, Okumup S, Kartal M 2007 Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 61:45-51
14. Kahaly GJ, Pitz S, Hommel G, Dittmar M 2005 Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90:5234-5240
15. De Bellis A, Bizzarro A, Conte M, Coronella C, Solimeno S, Perrino S, Sansone D, Guaglione M, Wall JR, Bellastella A 2003 Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy. Clin Endocrinol (Oxf) 59:388-395
16. Arteaga E, López JM, Rodríguez JA, Michaud P, López G 1983 Effect of the combination of dexamethasone and sodium ipodate on serum thyroid hormones in Graves' disease. Clin Endocrinol (Oxf) 19:619-627
17. Gamstedt A, Kågedal B, Tegler L 1988 Serum free thyroid hormones are decreased by betamethasone treatment in Graves' disease. Horm Metab Res 20:54-56
18. Peter SA 1991 Remission of Graves' disease with hyperthyroidism by a combination of glucocorticoids and antithyroid drugs. J Natl Med Assoc 83:261-264
19. Barrère X, Valeix P, Preziosi P, Bensimon M, Pelletier B, Galan P, Hercberg S 2000 Determinants of thyroid volume in healthy French adults participating in the SU.VI.MAX cohort. Clin Endocrinol (Oxf) 52:273-278
20. Brent GA 2008 Clinical practice. Graves' disease. N Engl J Med 358:2594-2605
21. Raber W, Kmen E, Waldhäusl W, Vierhapper H 2000 Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 142:117-124
22. Quadbeck B, Hörmann R, Janssen OE, Mann K 2003 Medikamentose behandliung der immunehyperthreose (typ morbus Basedow) patientselektion, langzeitverlauf und rezidivprophylaxe. Internist 44:440-448
23. Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H 1998 Is there a methimazole dose effect on remission rate in Graves' disease? Results from a longterm prospective study. Clin Endocrinol (Oxf) 49:451-457
24. Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE 1998 Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J Clin Endocrinol Metab 83:814-818
25. Volpé R 2001 The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des 7:451-460
26. Balazs C, Kiss E, Leövey A, Farid NR 1986 The immunosuppressive effect of methimazole on cell-mediated immunity is mediated by its capacity to inhibit peroxidase and to scavenge free oxygen radicals. Clin Endocrinol Oxf 25:7-16
27. Cooper DS 2005 Antithyroid drugs. N Engl J Med 352:905-917
28. Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E 2006 Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16:295-302
29. Okamoto Y, Tanigawa S, Ishikawa K, Hamada N 2006 TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J 53:467-472
30. Nordyke RA, Gilbert Jr FI, Harada AS 1988 Graves' disease. Influence of age on clinical findings. Arch Intern Med 148:626-631
31. Aizawa T, Ishihara M, Hashizume K, Takasu N, Yamada T 1989 Age-related changes of thyroid function and immunologic abnormalities in patients with hyperthyroidism due to Graves' disease. J Am Geriatr Soc 37:944-948
32. Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H, Mann K, and the Basedow Study Group 2002 Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid 12:1119-1128